Client retention in the British Columbia methadone program, 1996-1999

被引:42
作者
Anderson, JE
Warren, LD
机构
[1] Govt British Columbia, Mental Hlth & Addict Div, BC Minist Hlth Serv, Victoria, BC V8W 3C8, Canada
[2] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada
来源
CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE | 2004年 / 95卷 / 02期
关键词
D O I
10.1007/BF03405776
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Methadone treatment for heroin addiction has been available for 40 years, but there is relatively little research on the effectiveness of Canadian programs. This paper describes one-year retention among the client cohorts entering the British Columbia Methadone Program during expansion between 1996 and 1999, and examines some factors previously shown to influence retention. Methods: All methadone maintenance prescriptions dispensed to 1996-1999 program entrants were extracted from records of the BC Triplicate Prescription Program. Retention status and covariates were evaluated one year post-entry using logistic regression. Effects of retention status misclassification on time in the program were assessed with a Cox model for clients who received continuous daily dosing or short carries. Results: Fifty-two percent of program entrants were still receiving methadone one year after entry; 24% had left the program at one year but later returned. Age at program entry and average daily dose of methadone were important predictors of continuation. In the logistic regression, only the 1999 year-of-entry cohort appeared to have a different retention trajectory. Year of entry is not a significant predictor of time in the program for those receiving daily or short carry doses only, and other results are consistent between models. Interpretation: Retention rates in the BC Methadone Program are favourable and consistent with published rates. Program expansion does not reduce retention, once the effects of client age and dose are accounted for. Adequate daily dosing appears crucial to both initial retention and return to treatment.
引用
收藏
页码:104 / 109
页数:6
相关论文
共 12 条
[11]   Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency [J].
Rhoades, HM ;
Creson, D ;
Elk, R ;
Schmitz, J ;
Grabowski, J .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (01) :34-39
[12]   Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area [J].
Thiede, H ;
Hagan, H ;
Murrill, CS .
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2000, 77 (03) :331-345